-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased significantly in the past decade
.
NAFLD has become the main cause of liver cirrhosis and hepatocellular carcinoma (HCC)
The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased significantly in the past decade
Researchers conducted a retrospective study in 2 tertiary medical centers in the United States, including NASH-related advanced liver fibrosis (bridging fibrosis [F3] and liver cirrhosis during follow-up from July 2002 to June 2016 [F4]) Patients
.
Statistical analysis was performed on the time of the patient’s last abdominal imaging examination, liver transplantation or HCC diagnosis
diagnosis
A total of 1072 patients were included in this study: 122 F3 stage fibrosis patients and 950 liver cirrhosis patients
.
In F3 patients, the occurrence of HCC was not observed during the follow-up period
The results of this study indicate that patients with NASH and bridging fibrosis have a lower risk of HCC
.
The use of dose-dependent statins significantly reduces the risk of HCC in patients with NASH liver cirrhosis
The results of this study indicate that patients with NASH and bridging fibrosis have a lower risk of HCC
Original source:
Pinyopornpanish, Kanokwan.
Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis.
Leave a message here
